CHPA Statement Regarding Melatonin

Share page:

Press Releases and Statements | Nov 12, 2020

Melatonin is a safe and popular ingredient found in several sleep-related dietary supplement products. It has been the focus of scientific study for over 60 years, primarily concerning its effects on sleep patterns and circadian rhythms and more recently on its association with immune and inflammatory system response. We are not aware, however, of any published clinical evidence to support its use in preventing or treating COVID-19. A recent article in PLOS Biology reports the results of a study using computer modeling to determine possible associations between melatonin and COVID-19, and while these computational models provide early insights, the authors are careful to note that large scale clinical trials are needed to assess whether melatonin would provide any benefit in COVID-19 prevention or treatment.

“When used appropriately, dietary supplements — including melatonin — can play an important role in personal healthcare, but inappropriate use of supplements could be harmful. Consumers should be wary of dietary supplement products making unsubstantiated and irresponsible claims regarding the prevention and treatment of COVID-19. Consumers should also use caution when reading news reports related to potential COVID-19 therapies. If you suspect you or someone you know has COVID-19, contact your healthcare provider immediately.”

Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system more than $7, contributing a total of $146 billion in savings each year. CHPA is committed to empowering consumer self-care by preserving and expanding choice and availability of consumer healthcare products. www.chpa.org